ReviewJournal of market access & health policy2017
Towards a more comprehensive approach for a total economic assessment of vaccines?: 1. The building blocks for a health economic assessment of vaccination.
Review in Journal of market access & health policy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Optimizing childhood vaccination coverage in Lubumbashi: Expert perspectives on the SCAVA / VACCIN+CONNECT- OS initiative.Human vaccines & immunotherapeutics · 2026Article
- Proposed Conceptual and Experience-Based Framework for Reaching an Optimal Vaccine Launch Strategy.Vaccines · 2026Article
- Health economic evaluation of 2-dose and 3-dose rotavirus vaccines in children below 5 years of age in Morocco.Human vaccines & immunotherapeutics · 2024Article
- Economic Evaluation of Rotavirus Vaccination in Children Aged Under Five Years in South Africa.Clinical drug investigation · 2023Article
- Article
- The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections.Clinical microbiology reviews · 2023Review
- Discounting health gain: a different view.Journal of market access & health policy · 2023Article
- Using Health Economics to Inform Immunization Policy Across All Levels of Government.PharmacoEconomics - open · 2022Article
- mRNA vaccines: A novel weapon to control infectious diseases.Frontiers in microbiology · 2022Review
- Perspectives on RNA Vaccine Candidates for COVID-19.Frontiers in molecular biosciences · 2021Review
- SMART Vaccines 2.0 decision-support platform: a tool to facilitate and promote priority setting for sustainable vaccination in resource-limited settings.BMJ global health · 2020Review
- Health technology assessment and priority setting for universal health coverage: a qualitative study of stakeholders' capacity, needs, policy areas of demand and perspectives in Nigeria.Globalization and health · 2020Article
- How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future.Journal of market access & health policy · 2020Review
- mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Review
- 2. How is the economic assessment of vaccines performed today?Journal of market access & health policy · 2017Review
- 3. How comprehensive can we be in the economic assessment of vaccines?Journal of market access & health policy · 2017Review
- Exploring the Use of a General Equilibrium Method to Assess the Value of a Malaria Vaccine: An Application to Ghana.MDM policy & practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since we were born, we all take preventative actions to avoid unpredictable adverse conditions. Some actions are done automatically. Others require a conscious choice , either for personal or social benefit. A distinction can therefore be drawn between non-active and active prevention, and between individual and social prevention. Active prevention requires making a choice in time, effort, and cost. We call it an economic choice. Vaccines belong to the group of active and social prevention. Because a vaccination program is an economic social choice, how should it be valued, and what cost should we pay for? To date, the economic evaluations developed for treatment have been applied to vaccines. However, over 25 different characteristics differentiate vaccines from treatment. For example, the benefit of vaccination is measured at the population level not at the individual level, the main effect of prevention is societal and not an individual-based gain only, and the biggest hurdle to implement a new vaccine is the initial budget investment and not so much its estimated 'value for money'. This makes the current application of incremental cost-utility analysis difficult for vaccines for a comprehensive evaluation. New approaches may be needed to capture the full economic benefit of vaccines..
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.